apg4a antikoerper, autl2 antikoerper, F6E13.27 antikoerper, APG4A antikoerper, zgc:111958 antikoerper, Aut2a antikoerper, AUTL2 antikoerper, AI627006 antikoerper, AV169859 antikoerper, Apg4a antikoerper, Atg4al antikoerper, Autl2 antikoerper, Atg4a antikoerper, autophagy related 4A cysteine peptidase L homeolog antikoerper, autophagy related 4A cysteine peptidase antikoerper, Peptidase family C54 protein antikoerper, ATG4 autophagy related 4 homolog A (S. cerevisiae) antikoerper, autophagy related 4A, cysteine peptidase antikoerper, atg4a.L antikoerper, ATG4A antikoerper, AT2G44140 antikoerper, atg4a antikoerper, Atg4a antikoerper
Hintergrund
Macroautophagy is the major inducible pathway for the general turnover of cytoplasmic constituents in eukaryotic cells, it is also responsible for the degradation of active cytoplasmic enzymes and organelles during nutrient starvation. Macroautophagy involves the formation of double-membrane bound autophagosomes which enclose the cytoplasmic constituent targeted for degradation in a membrane bound structure, which then fuse with the lysosome (or vacuole) releasing a single-membrane bound autophagic bodies which are then degraded within the lysosome (or vacuole). APG4A is a cysteine protease required for autophagy, which cleaves the C-terminal part of either MAP1LC3, GABARAPL2 or GABARAP, allowing the liberation of form I. A subpopulation of form I is subsequently converted to a smaller form (form II). Form II, with a revealed C-terminal glycine, is considered to be the phosphatidylethanolamine (PE)-conjugated form, and has the capacity for the binding to autophagosomes. Preferred substrate is GABARAPL2 followed by MAP1LC3A and GABARAP.